- Ticker
- ABOS
- Price
- 6.57
- Stock movement up
- +1.24 (23.26%)
- Company name
- Acumen Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 268.88M
- Ent value
- 117.95M
- Price/Sales
- -
- Price/Book
- 1.37
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 31.14%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2023-01-31
DIVIDENDS
ABOS does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.37 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 40.93M |
| EPS (TTM) | -0.95 |
| FCF per share (TTM) | -0.69 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -39.40M |
| Net income (TTM) | -38.34M |
| EPS (TTM) | -0.95 |
| EPS (1y forward) | -1.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 157.54M |
| Net receivables | 121.00K |
| Total current assets | 202.56M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 203.26M |
| Accounts payable | 2.08M |
| Short/Current long term debt | 133.00K |
| Total current liabilities | 6.61M |
| Total liabilities | 6.61M |
| Shareholder's equity | 196.65M |
| Net tangible assets | 196.65M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.59M |
| Capital expenditures (TTM) | 158.00K |
| Free cash flow (TTM) | -27.75M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -19.50% |
| Return on Assets | -18.86% |
| Return on Invested Capital | -19.48% |
| Cash Return on Invested Capital | -14.10% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.38 |
| Daily high | 6.66 |
| Daily low | 5.35 |
| Daily Volume | 362K |
| All-time high | 20.28 |
| 1y analyst estimate | 15.83 |
| Beta | - |
| EPS (TTM) | -0.95 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 27 Mar 2023 |
Downside potential
Loading...
Downside potential data
| ABOS | S&P500 | |
| Current price drop from All-time high | -67.60% | -14.91% |
| Highest price drop | -84.81% | -56.47% |
| Date of highest drop | 11 May 2022 | 9 Mar 2009 |
| Avg drop from high | -60.07% | -11.49% |
| Avg time to new high | 399 days | 13 days |
| Max time to new high | 398 days | 1805 days |
COMPANY DETAILS
Marketcap
268.88M
Marketcap category
Small-cap
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Here is how Novo Nordisk (NVO) and Acumen Pharmaceuticals, Inc. (ABOS) have performed compared to their sector so far this year.
January 6, 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
January 4, 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call Transcript November 14, 2022 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.26 EPS, expectations wer...
December 29, 2022
INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease continues to progress Acumen anticipates completing enrollment in the first quarter of 2023 and reporting to...
November 14, 2022
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel tar...
November 9, 2022
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel tar...
November 7, 2022
Clinical development plan published in Journal of Prevention of Alzheimer’s DiseaseCHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ...
November 1, 2022
CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that ACU193, the first clinical-stage monoclonal antibody that sele...
October 24, 2022
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
September 8, 2022
Thank you for standing by, and welcome to the Acumen Pharmaceuticals second quarter 2022 update call. Thank you for joining us today to review Acumen's second quarter 2022 update on operational progr...
August 16, 2022
Next page